e-learning
resources
ERJ
2015
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes David S., Chew Terrence, Flaherty Kevin R., Frye Sarah, Gibson Kevin F., Kaminski Naftali, Klemsz Michael J., Lange Wade, Noth Imre, Rothhaar Katia
Source:
Eur Respir J 2015; 45: 1393-1402
Journal Issue:
May
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Wilkes David S., Chew Terrence, Flaherty Kevin R., Frye Sarah, Gibson Kevin F., Kaminski Naftali, Klemsz Michael J., Lange Wade, Noth Imre, Rothhaar Katia. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1393-1402
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
The cryoTBB role in the diagnostic work-up of IPF: an European perspective; emergent standardization guidelines
Acute exacerbations of IPF: A neglected threat in IPF ?
Related content which might interest you:
Collagen V nasal tolerance promotes decrease in topoisomerase-1 and pulmonary fibrosis of systemic sclerosis model
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
Collagen V and decorin is involved in systemic sclerosis pulmonary fibrosis
Source: Annual Congress 2011 - The ageing pulmonary interstitium
Year: 2011
Systemic sclerosis patients‘ sera recognize collagen V in experimental scleroderma lung fibrosis
Source: Annual Congress 2011 - The ageing pulmonary interstitium
Year: 2011
Serum type III procollagen peptide in idiopathic pulmonary fibrosis: peptide levels and anti-fibrosis therapy
Source: Eur Respir J 2005; 26: Suppl. 49, 30s
Year: 2005
Improvement in pulmonary function after IV antibiotic treatment in cystic fibrosis patients
Source: Eur Respir J 2002; 20: Suppl. 38, 342s
Year: 2002
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Effect of nintedanib on hyaluronic acid metabolism in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Abnormal collagen type V deposition in lung fibroblast is correlated with a worse pulmonary function in systemic sclerosis
Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases
Year: 2007
Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019
Year: 2019
Late stage of experimental pulmonary fibrosis is modulated by collagen V
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Serum levels of a MMP-12 generated type IV collagen fragment is elevated in COPD and IPF patients
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Assessment of collagen in human idiopathic pulmonary fibrosis using second harmonics on Genesis 200
Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias
Year: 2018
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
Type V collagen nasal tolerance regulates collagen mRNA synthesis in pulmonary remodeling of experimental systemic sclerosis
Source: Annual Congress 2008 - Interstitial lung disease in systemic and vascular disorders
Year: 2008
Differential metabolism of hyaluronic acid in patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept